IL94990A - Pharmaceutical compositions for the prophylaxis and/or treatment of benign porstatic hyperplasia - Google Patents

Pharmaceutical compositions for the prophylaxis and/or treatment of benign porstatic hyperplasia

Info

Publication number
IL94990A
IL94990A IL9499090A IL9499090A IL94990A IL 94990 A IL94990 A IL 94990A IL 9499090 A IL9499090 A IL 9499090A IL 9499090 A IL9499090 A IL 9499090A IL 94990 A IL94990 A IL 94990A
Authority
IL
Israel
Prior art keywords
treatment
pharmaceutical compositions
hyperplasia
benign
porstatic
Prior art date
Application number
IL9499090A
Other languages
English (en)
Other versions
IL94990A0 (en
Original Assignee
Endorecherche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorecherche Inc filed Critical Endorecherche Inc
Publication of IL94990A0 publication Critical patent/IL94990A0/xx
Publication of IL94990A publication Critical patent/IL94990A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fertilizers (AREA)
  • Medicinal Preparation (AREA)
IL9499090A 1989-07-07 1990-07-06 Pharmaceutical compositions for the prophylaxis and/or treatment of benign porstatic hyperplasia IL94990A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37670089A 1989-07-07 1989-07-07

Publications (2)

Publication Number Publication Date
IL94990A0 IL94990A0 (en) 1991-06-10
IL94990A true IL94990A (en) 1997-01-10

Family

ID=23486098

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9499090A IL94990A (en) 1989-07-07 1990-07-06 Pharmaceutical compositions for the prophylaxis and/or treatment of benign porstatic hyperplasia

Country Status (17)

Country Link
US (1) US5817649A (ja)
EP (3) EP0943328B1 (ja)
JP (2) JP3332377B2 (ja)
KR (1) KR920703063A (ja)
AT (2) ATE269066T1 (ja)
AU (2) AU643445B2 (ja)
CA (1) CA2062973C (ja)
DE (2) DE69034148T2 (ja)
DK (2) DK0480950T3 (ja)
ES (2) ES2133270T3 (ja)
HU (1) HU223662B1 (ja)
IE (2) IE990530A1 (ja)
IL (1) IL94990A (ja)
MY (1) MY106484A (ja)
NZ (1) NZ234414A (ja)
WO (1) WO1991000731A1 (ja)
ZA (1) ZA905312B (ja)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204337A (en) * 1988-10-31 1993-04-20 Endorecherche Inc. Estrogen nucleus derivatives for use in inhibition of sex steroid activity
CA2062792C (en) * 1989-07-07 2006-03-21 Fernard Labrie Treatment of androgen-related diseases
IL101245A0 (en) * 1991-03-20 1992-11-15 Merck & Co Inc Pharmaceutical compositions for the treatment of prostatic cancer
WO1992018132A1 (en) * 1991-04-17 1992-10-29 Merck & Co., Inc. Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
US5175155A (en) * 1991-10-07 1992-12-29 Sterling Winthrop Inc. Win 49596-finasteride method of use and compositions
GB9506678D0 (en) * 1995-03-31 1995-05-24 Glaxo Inc Substituted 6-azacholesten-3-ones
US5780435A (en) 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
EP1321146A3 (en) * 1998-03-11 2004-06-02 Endorecherche Inc. Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use
PL343862A1 (en) 1998-03-11 2001-09-10 Endorech Inhibitors of type 5 and type 3 17β−hydroxysteroid dehydrogenase and methods for their use
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
US6268377B1 (en) * 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
US8278291B1 (en) 1999-08-13 2012-10-02 Curadis Gmbh Treatment of wrinkles and strias with 4-hydroxyandrostenedione or a derivative thereof
US6200573B1 (en) 1999-12-03 2001-03-13 Starcor Pharmaceuticals, Inc. Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia
US7001911B2 (en) 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
IL152719A0 (en) * 2000-06-28 2003-06-24 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7018993B2 (en) * 2000-06-30 2006-03-28 Chugai Seiyaku Kabushiki Kaisha Antiandrogenic agent
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
EP1854798A3 (en) 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
WO2002089802A2 (en) 2001-05-08 2002-11-14 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
US7015253B2 (en) * 2001-07-10 2006-03-21 American Medical Systems, Inc. Regimen for treating prostate tissue and surgical kit for use in the regimen
DK1423381T3 (da) 2001-09-06 2007-05-07 Schering Corp 17beta-hydroxysteroid-dehydrogenase type 3-inhibitorer til behandling af androgenafhængige sygdomme
AR036812A1 (es) 2001-10-17 2004-10-06 Schering Corp Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos para el tratamiento de enfermedades androgeno-dependientes
AU2002364082A1 (en) 2001-12-19 2003-07-09 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
CA2506290C (en) 2002-11-18 2012-04-24 Schering Corporation 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
JP4585320B2 (ja) 2002-12-17 2010-11-24 シェーリング コーポレイション 男性ホルモン依存性疾患の処置のための１７β−ヒドロキシステロイドデヒドロゲナーゼ３型インヒビター
US20060258628A1 (en) * 2004-07-20 2006-11-16 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors, and SARMs and methods of use thereof
WO2006042409A1 (en) 2004-10-20 2006-04-27 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
US9232959B2 (en) 2007-01-02 2016-01-12 Aquabeam, Llc Multi fluid tissue resection methods and devices
EP2099375B1 (en) 2007-01-02 2014-09-24 AquaBeam LLC Minimally invasive devices for the treatment of prostate diseases
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
GB0722779D0 (en) 2007-11-20 2008-01-02 Sterix Ltd Compound
WO2009111736A1 (en) 2008-03-06 2009-09-11 Aquabeam Llc Tissue ablation and cautery with optical energy carried in fluid stream
US9848904B2 (en) 2009-03-06 2017-12-26 Procept Biorobotics Corporation Tissue resection and treatment with shedding pulses
WO2014127242A2 (en) 2013-02-14 2014-08-21 Procept Biorobotics Corporation Aquablation aquabeam eye surgery methods and apparatus
JP6080872B2 (ja) 2012-02-29 2017-02-15 プロセプト バイオロボティクス コーポレイション 自動化された画像誘導組織切除および治療
CA2865234A1 (en) * 2012-02-29 2013-09-06 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
CN109965976B (zh) 2013-09-06 2022-05-31 普罗赛普特生物机器人公司 利用致脱脉冲的用于消融组织的装置
BR112016031037B1 (pt) 2014-06-30 2023-02-07 Procept Biorobotics Corporation Aparelho para ablação de tecido vascular
JP2017532095A (ja) 2014-09-05 2017-11-02 プロセプト バイオロボティクス コーポレイション 標的器官画像の処理マッピングと一体化された医師制御組織切除

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329364A (en) * 1974-09-11 1982-05-11 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
US4039669A (en) * 1975-08-01 1977-08-02 Sterling Drug Inc. Composition for topical application and use thereof
US4087461A (en) * 1976-02-26 1978-05-02 The Johns Hopkins University Anti-androgenic steroids
DE2817157A1 (de) * 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
US4235893A (en) * 1978-05-08 1980-11-25 Brodie Angela M Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis
FR2465486A1 (fr) * 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
US4474813A (en) * 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
DE3121152A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie"
DE3121153A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie"
US4347363A (en) * 1981-09-17 1982-08-31 Sterling Drug Inc. Process for preparing 1,2-dihydro-6-methyl-2-oxo-5-(pyridinyl)nicotinonitriles
DE3339295A1 (de) * 1982-11-15 1984-05-17 Schering AG, 1000 Berlin und 4709 Bergkamen 4-hydroxy- und 4-acyloxy-4-androsten-3,17-dione zur verwendung bei der prophylaxe und therapie der prostatahyperplasie und diese enthaltende mittel fuer derartige verwendung
AU565915B2 (en) * 1982-12-31 1987-10-01 Mortimer, C.H. Pharmaceutical composition of antibiotic and anti- androgen
DE3323321A1 (de) * 1983-06-24 1985-01-03 Schering AG, 1000 Berlin und 4709 Bergkamen Prophylaxe und therapie von koronaren herzkrankheiten durch senkung des oestrogenspiegels
JPH0745382B2 (ja) * 1983-12-12 1995-05-17 カスジンスキ−，エドウイン ジ−． 毛の生長の改良
US5053403A (en) * 1984-05-11 1991-10-01 Norman Orentreich Methods for treatment of male-pattern baldness
US4684635A (en) * 1984-05-11 1987-08-04 Norman Orentreich Compositions and methods for inhibiting the action of androgens
US4659695A (en) * 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
AU594309B2 (en) * 1984-08-02 1990-03-08 Fernand Labrie Pharmaceutical composition for combination therapy of hormonedependent cancers
DE3478398D1 (en) * 1984-10-10 1989-07-06 Ile De France Synergistic contraceptive mixture
GB8503940D0 (en) * 1985-02-15 1985-03-20 Erba Farmitalia 4-substituted androstendione derivatives
GB8505862D0 (en) * 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors
DE3607651A1 (de) * 1986-03-06 1987-09-10 Schering Ag Kombination von aromatasehemmer und testosteron-5(alpha)-reduktase-hemmer
IE60964B1 (en) * 1986-12-11 1994-09-07 Roussel Uclaf Zootechnical compositions containing a beta-adrenergic
US4888336A (en) * 1987-01-28 1989-12-19 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
DE3888378T2 (de) * 1987-04-03 1994-09-29 Merck & Co Inc Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia

Also Published As

Publication number Publication date
DE69033020T2 (de) 1999-08-05
EP0943328B1 (en) 2004-06-16
ZA905312B (en) 1992-02-26
ES2133270T3 (es) 1999-09-16
IE902459A1 (en) 1991-02-13
EP0857487A3 (en) 1999-12-08
US5817649A (en) 1998-10-06
MY106484A (en) 1995-05-30
EP0480950A1 (en) 1992-04-22
JP3332377B2 (ja) 2002-10-07
IE990531A1 (en) 2000-11-15
AU5217493A (en) 1994-02-10
DE69034148D1 (de) 2004-07-22
EP0857487A2 (en) 1998-08-12
DK0480950T3 (da) 1999-10-11
AU643445B2 (en) 1993-11-18
JP2001354590A (ja) 2001-12-25
ES2222633T3 (es) 2005-02-01
EP0943328A3 (en) 1999-12-08
ATE177949T1 (de) 1999-04-15
EP0943328A2 (en) 1999-09-22
JPH04506798A (ja) 1992-11-26
CA2062973C (en) 2003-09-23
WO1991000731A1 (en) 1991-01-24
IE990530A1 (en) 2000-11-15
DE69033020D1 (de) 1999-04-29
AU668434B2 (en) 1996-05-02
HU9200047D0 (en) 1992-06-29
IL94990A0 (en) 1991-06-10
DK0943328T3 (da) 2004-10-18
NZ234414A (en) 1999-05-28
EP0480950B1 (en) 1999-03-24
CA2062973A1 (en) 1991-01-08
HU223662B1 (hu) 2004-11-29
DE69034148T2 (de) 2005-06-30
AU5854590A (en) 1991-02-06
KR920703063A (ko) 1992-12-17
ATE269066T1 (de) 2004-07-15
HUT60138A (en) 1992-08-28

Similar Documents

Publication Publication Date Title
IL94990A (en) Pharmaceutical compositions for the prophylaxis and/or treatment of benign porstatic hyperplasia
MX9702380A (es) Nuevas carboxamidas con actividad antifungica.
GEP20063885B (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
IL87885A (en) Pharmaceutical compositions having antiprogestational and anti-estrogenic activities for the treatment of hormone- dependent tumors
HK1036931A1 (en) Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients.
CA2245142A1 (en) New phenanthridines
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
MX9702382A (es) Nuevos derivados de pirimidona con actividad antifungica.
HK1029922A1 (en) Angiostatic agents and compositions for treating glc1a glaucoma
CY2431B1 (en) Novel phenanthridines substituted in the 6 position.
IL101574A0 (en) Combination pharmaceutical compositions for the treatment of benign prostatic hyperplasia
EP0646007A1 (en) NEW DELTA-17 AND DELTA-20 UNSATURATED AND SATURATED 17 - g (b) -SUBSTITUTED-4-AZA-5-g (a) -ANDROSTAN-3-ON COMPOUNDS AS INHIBITORS OF 5-ALPHA REDUCTASE.
MX9604434A (es) Productos farmaceuticos y medicamentos para la prevencion y el tratamiento de disfunciones endoteliales.
BG105256A (en) Muscarinic agonists and antagonists
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
DE58902899D1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
IL105475A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 1a, 24(R) - DIHYDROXY-22(E)-DEHYDRO- VITAMIN D3 FOR TREATING OSTEOPOROSIS
IL109866A (en) Crystalline 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine(+)L-hydrogentartrate its preparation and pharmaceutical compositions containing it
LT96094A (en) The active ingredient of pharmaceutical composition for treating constipation
DE59101818D1 (de) Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung.
ATE82855T1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosidphosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed